266 related articles for article (PubMed ID: 35667864)
1. Current data on the efficacy of prophylactic HPV vaccination in the primary prevention of cervical lesions.
Sehnal Borek; Driák Daniel; Džubáková Nipčová Monika; Sláma Jiří
Ceska Gynekol; 2022; 87(2):124-130. PubMed ID: 35667864
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of human papillomavirus vaccination in the prevention of recurrence of severe cervical lesions.
Sehnal Borek; Pichlík Tomáš; Halaška Michael J; Větrovská Monika; Babková Anna; Drozenová Jana; Robová Helena; Rob Lukáš
Ceska Gynekol; 2023; 88(4):294-300. PubMed ID: 37643912
[TBL] [Abstract][Full Text] [Related]
3. [Anticipated efficacy of HPV vaccination in prophylaxis against nongenital cancers].
Sehnal B; Vojáčková N; Driák D; Kmoníčková E; Vaňousová D; Maxová K; Neumannová H; Sláma J
Klin Onkol; 2014; 27(4):239-46. PubMed ID: 25115712
[TBL] [Abstract][Full Text] [Related]
4. Vaccination against HPV and view of new possibilities.
Mladěnka A; Sláma J
Ceska Gynekol; 2018; 83(3):218-225. PubMed ID: 30764623
[TBL] [Abstract][Full Text] [Related]
5. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer.
Kamolratanakul S; Pitisuttithum P
Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960159
[TBL] [Abstract][Full Text] [Related]
6. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
8. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
9. Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.
Mandic A
J BUON; 2012; 17(3):422-7. PubMed ID: 23033276
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
McIntosh J; Sturpe DA; Khanna N
J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
[TBL] [Abstract][Full Text] [Related]
11. HPV-vaccination against cervical carcinoma: will it really work?
Gross G
Med Microbiol Immunol; 2007 Sep; 196(3):121-5. PubMed ID: 17318575
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
[TBL] [Abstract][Full Text] [Related]
13. [What should be known for the introduction of an HPV vaccine?].
Muñoz N; Jacquard AC
Presse Med; 2008 Oct; 37(10):1377-90. PubMed ID: 18786806
[TBL] [Abstract][Full Text] [Related]
14. HPV vaccines - A review of the first decade.
Harper DM; DeMars LR
Gynecol Oncol; 2017 Jul; 146(1):196-204. PubMed ID: 28442134
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of human papillomavirus vaccines and beyond.
Lehtinen M; Dillner J
Nat Rev Clin Oncol; 2013 Jul; 10(7):400-10. PubMed ID: 23736648
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
17. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
18. [The importance of HPV vaccination in men].
Sehnal B; Chlíbek R; Sláma J
Cas Lek Cesk; 2016; 155(4):34-9. PubMed ID: 27481200
[TBL] [Abstract][Full Text] [Related]
19. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
20. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
